Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

Bio-Thera Solutions Receives NMPA Approval for Three Cancer Treatments Including a Novel ADC

Fineline Cube Mar 6, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, has received separate clinical trial approvals...

Policy / Regulatory

China’s Government Work Report Highlights Biomedicine Innovation and Healthcare Reforms

Fineline Cube Mar 5, 2024

Chinese Premier Li Qiang presented a concise Government Work Report at the Second Session of...

Company Drug

EMA Reviews Datopotamab Deruxtecan Filings from AstraZeneca and Daiichi Sankyo for Oncology Indications

Fineline Cube Mar 5, 2024

The European Medicines Agency (EMA) has accepted for review two oncology filings for the antibody-drug...

Company Drug

Pfizer’s Cibinqo Secures NMPA Approval for Expanded Use in Atopic Dermatitis

Fineline Cube Mar 5, 2024

The National Medical Products Administration (NMPA) has released drug approval certificate delivery information that points...

Policy / Regulatory

China Aims to Insure 80% of Newborns with Basic Medical Insurance by 2024

Fineline Cube Mar 5, 2024

The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC), along with three...

Company Drug

Novartis Gene Therapy Zolgensma Shows Continued Benefits in Broader SMA Patient Group

Fineline Cube Mar 5, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented Phase III data this week, demonstrating that...

Company Deals

Bitterroot Bio and Biotheus Inc. Join Forces to Develop Therapies for Cardiovascular Diseases

Fineline Cube Mar 5, 2024

California-based biotechnology company Bitterroot Bio has announced the signing of a multi-year research collaboration agreement...

Company Drug

Luye Pharma Initiates Phase III Clinical Trial for Irinotecan Liposome Injection in Small-Cell Lung Cancer

Fineline Cube Mar 5, 2024

Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the enrollment of the...

Company

Henlius Biotech Forecasts First-Ever Profit in 2023 Driven by Sales Growth and Efficient Management

Fineline Cube Mar 5, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a China-based biopharmaceutical company, has released a positive profit...

Company Deals

Nuance Pharma Wins Arbitration, Rescinds Licensing Deal with Antibe Therapeutics

Fineline Cube Mar 5, 2024

Nuance Pharma, a China-based pharmaceutical company, has received a favorable arbitration verdict from a Singapore...

Company Drug

Aosaikang’s Marketing Approval Filing for Delafloxacin Accepted by China’s NMPA

Fineline Cube Mar 5, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the...

Company Deals

Vivolight Medical Secures Over RMB 100 Million in Strategic Financing to Boost Global Expansion

Fineline Cube Mar 5, 2024

Shenzhen Vivolight Medical Device & Technology Co., Ltd, a Chinese medical device company nurtured and...

Company Drug

Huadong Medicine’s Arcalyst Filing for Recurrent Pericarditis Accepted by China’s NMPA

Fineline Cube Mar 5, 2024

Huadong Medicine Co., Ltd, (SHE: 000963) a Chinese pharmaceutical company, has announced that the National...

Company Medical Device

Sino Medical Sciences Receives Hong Kong Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Mar 5, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Green Light for KRAS G12C Inhibitor Clinical Trial in Advanced Solid Tumors

Fineline Cube Mar 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Drug

HitGen Secures CDE Approval for Lipisense IND Filing, Advancing Development for Dyslipidemia Treatment

Fineline Cube Mar 5, 2024

HitGen Inc., (SHA: 688222) a China-based pharmaceutical company, has announced that the Investigational New Drug...

Company Drug

ViiV Healthcare Presents Phase I Data for Ultra-Long-Acting Cabotegravir in HIV Treatment and Prevention

Fineline Cube Mar 5, 2024

GlaxoSmithKline (GSK; NYSE: GSK) unit ViiV Healthcare has presented Phase I results for an ultra-long-acting...

Company Deals

Merck Teams Up with C4 Therapeutics for Targeted Protein Degraders in Oncology

Fineline Cube Mar 5, 2024

Merck (NYSE: MRK), a Germany-headquartered science and technology company, has entered into a partnership with...

Company Digital

Innovent Biologics’ Taletrectinib Receives Second NDA Acceptance in China for ROS1 Positive NSCLC

Fineline Cube Mar 5, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that the...

Company Drug

BMS Reports Positive Long-Term Data for Zeposia in Multiple Sclerosis Trials

Fineline Cube Mar 4, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has unveiled results from several Phase III trials for...

Posts pagination

1 … 389 390 391 … 661

Recent updates

  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
  • Kexing Pharmaceutical Launches HKEX Secondary Offering – Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline
  • Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer
  • Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Others

Kexing Pharmaceutical Launches HKEX Secondary Offering – Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline

Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.